NCT03095703 2024-10-24
Sirolimus and Familial Adenomatous Polyposis (FAP)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Completed
Clinical Trials
12 trialsNCT00151476 2024-09-04
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
Pfizer
Terminated
NCT00503035 2023-02-13
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02961374 2022-07-26
Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01483144 2021-06-08
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Cancer Prevention Pharmaceuticals, Inc.
Phase 3 Completed
NCT00585312 2021-02-21
CHIP
Pfizer
Phase 3 Terminated
NCT00927485 2020-12-16
Use of Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)
University of Puerto Rico
Phase NA Completed
NCT00033371 2020-09-29
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Completed
NCT00663819 2018-04-17
Bioabsorbable Staple Line Reinforcement in Colorectal,Coloanal and Ileoanal Anastomoses
W.L.Gore & Associates
Phase NA Terminated
NCT01187901 2016-06-17
FAPEST
University of Utah
Phase 2 Completed
NCT01002287 2014-11-20
An Evaluation of SprayShield in Reducing Post-Operative Adhesion Formation Following Major Open Abdominal Surgery
Integra LifeSciences Corporation
Phase NA Terminated
NCT00510692 2014-08-22
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA
S.L.A. Pharma AG
Phase 2/3 Completed